BR112022014646A2 - Terapia anti-bcma em transtornos autoimunes - Google Patents
Terapia anti-bcma em transtornos autoimunesInfo
- Publication number
- BR112022014646A2 BR112022014646A2 BR112022014646A BR112022014646A BR112022014646A2 BR 112022014646 A2 BR112022014646 A2 BR 112022014646A2 BR 112022014646 A BR112022014646 A BR 112022014646A BR 112022014646 A BR112022014646 A BR 112022014646A BR 112022014646 A2 BR112022014646 A2 BR 112022014646A2
- Authority
- BR
- Brazil
- Prior art keywords
- autoimmune disorders
- bcma therapy
- bcma
- therapy
- anca
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975663P | 2020-02-12 | 2020-02-12 | |
| PCT/US2021/017665 WO2021163329A1 (en) | 2020-02-12 | 2021-02-11 | Anti-bcma therapy in autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014646A2 true BR112022014646A2 (pt) | 2022-09-13 |
Family
ID=77291870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014646A BR112022014646A2 (pt) | 2020-02-12 | 2021-02-11 | Terapia anti-bcma em transtornos autoimunes |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240052064A1 (https=) |
| EP (1) | EP4103224A4 (https=) |
| JP (1) | JP7783183B2 (https=) |
| KR (1) | KR20220141306A (https=) |
| CN (1) | CN115551539A (https=) |
| AU (1) | AU2021221123A1 (https=) |
| BR (1) | BR112022014646A2 (https=) |
| CA (1) | CA3169696A1 (https=) |
| IL (1) | IL295471A (https=) |
| MX (1) | MX2022009784A (https=) |
| WO (1) | WO2021163329A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2023044633A1 (zh) * | 2021-09-22 | 2023-03-30 | 南京驯鹿医疗技术有限公司 | Bcma car-t在制备用于治疗自身免疫病的药物中的应用 |
| WO2026033437A1 (en) * | 2024-08-07 | 2026-02-12 | Janssen Biotech, Inc. | Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics |
| WO2026037514A1 (en) * | 2024-08-13 | 2026-02-19 | Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern | A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3331910T1 (sl) * | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
| CA3287539A1 (en) * | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| SG11202003501XA (en) * | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
-
2021
- 2021-02-11 IL IL295471A patent/IL295471A/en unknown
- 2021-02-11 MX MX2022009784A patent/MX2022009784A/es unknown
- 2021-02-11 CA CA3169696A patent/CA3169696A1/en active Pending
- 2021-02-11 CN CN202180027778.XA patent/CN115551539A/zh active Pending
- 2021-02-11 WO PCT/US2021/017665 patent/WO2021163329A1/en not_active Ceased
- 2021-02-11 JP JP2022548786A patent/JP7783183B2/ja active Active
- 2021-02-11 US US17/798,983 patent/US20240052064A1/en active Pending
- 2021-02-11 BR BR112022014646A patent/BR112022014646A2/pt unknown
- 2021-02-11 AU AU2021221123A patent/AU2021221123A1/en active Pending
- 2021-02-11 KR KR1020227030166A patent/KR20220141306A/ko active Pending
- 2021-02-11 EP EP21754567.2A patent/EP4103224A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220141306A (ko) | 2022-10-19 |
| JP2023514224A (ja) | 2023-04-05 |
| US20240052064A1 (en) | 2024-02-15 |
| EP4103224A4 (en) | 2023-08-16 |
| CN115551539A (zh) | 2022-12-30 |
| JP7783183B2 (ja) | 2025-12-09 |
| MX2022009784A (es) | 2022-09-09 |
| IL295471A (en) | 2022-10-01 |
| WO2021163329A1 (en) | 2021-08-19 |
| CA3169696A1 (en) | 2021-08-19 |
| AU2021221123A1 (en) | 2022-10-06 |
| EP4103224A1 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014646A2 (pt) | Terapia anti-bcma em transtornos autoimunes | |
| Linderman et al. | Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season | |
| PH12015500435A1 (en) | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions | |
| BR112014011878A2 (pt) | sistema e método para controle de link de comunicação | |
| MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| MA38308B1 (fr) | Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t | |
| MA40510A (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t | |
| MX395639B (es) | Composiciones y métodos para el agotamiento de células cd137+. | |
| BR112012005970A2 (pt) | moduladores tricíclicos de proteína quinase | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| HN2010000202A (es) | Anticuarpos humanos contra cd20 humano y metodo para utilizarlos | |
| UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
| MX2016014210A (es) | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. | |
| BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
| Ljoså et al. | Mental distress among shift workers in Norwegian offshore petroleum industry—relative influence of individual and psychosocial work factors | |
| BR112022002142A2 (pt) | Anticorpos anti-bdca-2 | |
| EA201890340A1 (ru) | Моноклональное антитело-ингибитор фактора xiia | |
| BR112019000544A2 (pt) | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática | |
| BR112014027991A2 (pt) | agentes para neutralização de influenza | |
| BR112016003293A2 (pt) | anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos | |
| CL2023000823A1 (es) | Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4 | |
| CO2018010286A2 (es) | Método para la purificación de proteínas | |
| PA8827501A1 (es) | Pirrolidin amidas sustituidas como moduladores del receptor histamina h3 | |
| BR112022018945A2 (pt) | Tecnologias para prevenir ou tratar infecções |